NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular RiskZacks Investment Research • 09/30/26
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?Zacks Investment Research • 09/30/26
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world studyReuters • 09/30/26
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world studyCNBC • 09/30/26
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should KnowZacks Investment Research • 09/29/26
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?Zacks Investment Research • 09/29/26
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's MounjaroReuters • 09/29/26
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 09/25/26
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaringMarket Watch • 09/25/26